Results 31 to 40 of about 3,329,282 (264)
We evaluated circulating tumor DNA (ctDNA) detection in advanced pancreatic cancer using DNA methylation, cell‐free DNA fragment lengths, and 5′ end motifs. Machine learning models were trained to estimate ctDNA levels from each feature and their combination.
Morten Lapin +10 more
wiley +1 more source
Renewing the fight to end tuberculosis
The Lancet Public Health
doaj +1 more source
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern +7 more
wiley +1 more source
Health and inequity in Australia
The Lancet Public Health
doaj +1 more source
A bioinformatics screen identifies TCF19 as an aggressiveness‐sustaining gene in prostate cancer
Gene expression meta‐analysis in multiple prostate cancer patient cohorts identifies Transcription factor 19 (TCF19) as an aggressiveness‐sustaining gene with prognostic potential. TCF19 is a gene repressed by androgen signaling that sustains core cancer‐related processes such as vascular permeability or tumor growth and metastasis.
Amaia Ercilla +15 more
wiley +1 more source
COVID-19 in France: challenges and opportunities
The Lancet Public Health
doaj +1 more source
The Impact of Population Aging and Public Health Support on EU Labor Markets [PDF]
Mirela Cristea +3 more
openalex +1 more source
Using multi‐omic characterization, we aimed to identify key regulators specific to squamous cell lung carcinoma (SqCC). SqCC‐specific differentially expressed genes were integrated with metabolics data. High expression of the creatine transporter SLC6A8, along with elevated creatine levels, appeared to be a distinct metabolic feature of SqCC.
Johan Staaf +10 more
wiley +1 more source
COVID-19 hindering progress against female genital mutilation
The Lancet Public Health
doaj +1 more source
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser +14 more
wiley +1 more source

